| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.47B | 4.00B | 3.70B | 3.75B | 3.85B |
| Gross Profit | 3.12B | 3.49B | 3.26B | 3.28B | 3.37B |
| EBITDA | 1.86B | 1.48B | 1.39B | 1.64B | 1.84B |
| Net Income | 541.13M | 415.00M | -2.53B | -162.00M | 674.00M |
Balance Sheet | |||||
| Total Assets | 9.21B | 8.04B | 8.22B | 15.08B | 15.92B |
| Cash, Cash Equivalents and Short-Term Investments | 1.73B | 2.05B | 2.33B | 3.23B | 2.34B |
| Total Debt | 5.14B | 4.69B | 5.16B | 8.18B | 10.65B |
| Total Liabilities | 7.58B | 6.78B | 7.15B | 14.32B | 14.42B |
| Stockholders Equity | 1.34B | 1.10B | 858.00M | 569.00M | 586.00M |
Cash Flow | |||||
| Free Cash Flow | 630.64M | 523.00M | 1.58B | 1.92B | 1.94B |
| Operating Cash Flow | 1.38B | 1.15B | 2.11B | 2.56B | 2.64B |
| Investing Cash Flow | -804.58M | -778.00M | -2.24B | -1.66B | -1.46B |
| Financing Cash Flow | -557.41M | -551.00M | -1.15B | 116.00M | -465.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $5.34B | 10.60 | 7.24% | 5.57% | 19.02% | 9.26% | |
64 Neutral | $4.68B | 9.02 | 24.66% | 7.78% | 0.59% | 8.86% | |
60 Neutral | $48.67B | 4.58 | -11.27% | 4.14% | 2.83% | -41.78% | |
60 Neutral | $5.21B | -36.64 | -2.67% | 0.40% | 15.38% | -292.52% | |
60 Neutral | $4.04B | 15.83 | 8.13% | 42.91% | -25.64% | ― | |
58 Neutral | $3.37B | 6.97 | 40.63% | ― | 6.42% | ― | |
56 Neutral | $4.57B | -757.27 | -0.13% | 0.39% | -22.79% | 79.90% |
On March 16, 2026, VEON Ltd. announced it had filed its Annual Report on Form 20-F for the financial year ended December 31, 2025 with the U.S. Securities and Exchange Commission, following completion of an audit of its 2025 financial statements by independent auditor UHY LLP under PCAOB standards. The 2025 Form 20-F, which is now accessible via the SEC’s website and VEON’s own site, and available in hard copy on request to investors, marks an important step in maintaining the company’s U.S. listing compliance and transparency for shareholders monitoring its performance and governance.
The most recent analyst rating on (VEON) stock is a Hold with a $51.00 price target. To see the full list of analyst forecasts on VEON stock, see the VEON Stock Forecast page.
On March 13, 2026, VEON reported strong fourth-quarter and full-year 2025 results, driven by rapid expansion of its digital and financial services businesses. Fourth-quarter revenue rose 17.4% year-on-year to USD 1.17 billion and EBITDA grew 29.1%, while digital revenues surged 84.1% to represent 20.1% of group revenue, and full-year 2025 revenue and EBITDA increased 9.9% and 18.8% respectively, with digital contributing USD 759 million and a 17.3% revenue share.
The company coupled these results with balance sheet strengthening and active capital returns, including equity free cash flow after leases and licenses of USD 624 million, net debt to EBITDA reduced to 1.09x, and execution of a USD 100 million buyback alongside a second ongoing program. Strategic moves in 2025 and early 2026 — such as the Kyivstar secondary offering, acquisitions in Ukraine including Tabletki.ua, spectrum wins for Jazz in Pakistan, settlement of historic shareholder claims with Dhabi Group, index inclusions and a listing upgrade on Nasdaq — underline VEON’s shift toward a diversified digital operator model and aim to reinforce its market positioning ahead of its targeted mid‑single‑digit to low‑teens revenue and EBITDA growth in 2026.
The most recent analyst rating on (VEON) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on VEON stock, see the VEON Stock Forecast page.
On February 10, 2026, VEON’s Ukrainian subsidiary Kyivstar completed the acquisition of 100% of Tabletki.ua, one of Ukraine’s most widely used digital platforms for finding, comparing and reserving medicines, in a deal valued at USD 160 million payable in local currency. Tabletki.ua, which partners with over 14,000 pharmacies and handled an average 14 million reservations a month in 2025, recorded gross merchandise value of UAH 57.3 billion in the 12 months to September 30, 2025.
The acquisition deepens Kyivstar’s push into digital healthcare and broadens its consumer ecosystem, complementing its earlier Helsi deal and sitting alongside services like Kyivstar TV, Uklon and the MyKyivstar super-app. Based on unaudited accounts, Tabletki.ua generated last‑twelve‑month EBITDA of USD 24 million and net profit of USD 20 million, implying a price-to-earnings multiple of 8x, which underscores VEON’s strategic bet on scalable, profitable e‑health platforms in Ukraine’s recovering digital economy.
The most recent analyst rating on (VEON) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on VEON stock, see the VEON Stock Forecast page.
On January 29, 2026, VEON announced that Kyivstar Group Ltd., its Nasdaq-listed Ukrainian affiliate, had priced a secondary public offering of 12.1 million common shares held by VEON Amsterdam B.V. and 400,000 shares held by other shareholders at USD 10.50 per share. The underwriters were granted a 30‑day option to purchase up to an additional 1.875 million shares, and the offering, which does not involve Kyivstar issuing new shares, is expected to close on February 2, 2026, subject to customary conditions. The transaction, following the SEC’s declaration of effectiveness for Kyivstar’s Form F‑1 registration statement on January 29, 2026, represents a further step in building liquidity and broadening the shareholder base of Ukraine’s leading digital operator while allowing VEON and other owners to partially monetize their holdings without diluting the company’s capital structure.
The most recent analyst rating on (VEON) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on VEON stock, see the VEON Stock Forecast page.
On January 28, 2026, VEON Ltd. reported that its wholly owned subsidiary VEON Amsterdam B.V., together with other selling shareholders, is pursuing a public offering of common shares in Kyivstar Group Ltd. via a Form F-1 registration filed with the U.S. Securities and Exchange Commission. As part of this process, Kyivstar disclosed preliminary, unaudited estimates for the year ended December 31, 2025, indicating robust year-on-year revenue and adjusted EBITDA growth in the 24%-26% range in U.S. dollar terms and a capex intensity of 29%-31%. Although these figures remain subject to audit and final closing procedures, the filing underscores Kyivstar’s strong operational trajectory in Ukraine and highlights VEON’s efforts to crystallize value from its Ukrainian business, a key asset whose performance is closely watched by investors amid the country’s challenging macroeconomic and geopolitical environment.
The most recent analyst rating on (VEON) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on VEON stock, see the VEON Stock Forecast page.